{
  "docId": "019de075-a749-75ad-9c96-b2ef130e2f41",
  "docSlug": "810e8355c3b124b062a449d6b3848ba9",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 49 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 49,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-a749-75ad-9c96-b2ef130e2f41/19",
  "deckHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41",
  "deckJsonHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41.json",
  "deckAnchorHref": "/decks/019de075-a749-75ad-9c96-b2ef130e2f41#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.03,
        "y": 0.2
      },
      "kind": "list",
      "text": "92% Overall Response Rate in Heavily Pretreated Multiple Myeloma Patients 60% CR/sCR (sCR 10^-5) rate; No Neurotoxicity observed; 1 Grade 3, No Grade 4 Cytokine Release Syndrome (CRS) Observed at planned RP2D 800 million CAR+T cells; Outpatient CAR-T Potential",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53663b22-1804-45bf-9fd3-5d9cdac32366",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.53,
        "y": 0.2
      },
      "kind": "list",
      "text": "100% Overall Response + 75% Organ Response (Cardiac, renal, liver) in Relapsed/Refractory Amyloidosis Patients; Duration of Response Not Yet Reached at a median follow-up of 5.2 months; 2-stage improvement in NYHA stage; Mean 65% reduction in NT-proBNP",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc1d452d-6749-4d8e-bbc3-7fc9ba3e3f30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "metric",
      "text": "176,404 patient annual incidence",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f01f66d-b4f7-4e08-b256-ca57680824b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.53,
        "y": 0.82
      },
      "kind": "metric",
      "text": "14,982 patient annual incidence",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad58a675-df43-4c1a-8d97-d7c583329f5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: BMS First Quarter 2022 financial results; Genmab Improves Its 2022 Financial Guidance... [full citation]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53c00023-f32a-41dc-aa2f-4695311d071a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.03,
        "y": 0.6
      },
      "kind": "table",
      "text": "Market benchmarks for Multiple Myeloma therapies including Revlimid, Darzalex, Pomalyst, Abecma, and Carvykti with associated sales and status.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "623bce3a-9eab-4902-9d85-9a738f329c63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "NXC-201 Clinical Highlights: No Neurotoxicity Across 42 Patients; Outpatient CAR-T Potential",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "967286a9-3788-414a-b2e7-445f7262ef8d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "d84835a9-6df7-4b65-887a-1c9962dfb057",
      "evidence": "table/data: Market benchmarks for Multiple Myeloma therapies including Revlimid, Darzalex, Pomalyst, Abecma, and Carvykti with associated sales and status.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "8edcc9af-d057-497a-85bc-5cd80c6bf8f4",
      "evidence": "Side-by-side clinical data presentation for two distinct patient populations.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 21,
      "from": 8,
      "beatId": "a874b208-4408-43df-9863-8c8c163ed01d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Presentation of clinical data and competitive analysis for NXC-201",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6ea19383-9ed5-41d1-ac2b-d7d037efe2d8",
      "evidence": "Discussion of neurotoxicity associated with existing BCMA CAR-T therapies",
      "position": 0,
      "objective": "Highlighting the need for improved therapies",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 21,
      "from": 17,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "937d5537-d54e-4e3a-a66e-a14f52ce0de8",
      "evidence": "Discussion of NXC-201 entering large markets at a pivotal moment",
      "position": 2,
      "objective": "Explaining the timing of NXC-201's entry into the market",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}